YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Learn to distinguish between nail psoriasis and nail fungus through key visual differences, associated symptoms, and ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Formycon and its commercialization partner Fresenius Kabi have announced that the US Food and Drug Administration (FDA) has ...

When you think of signs that something is amiss with your health, your first thought may be aches and pains or even visible ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...

Pyzchiva® is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across ...

Moderate to severe psoriasis describes how much of ... What it is: An oral drug approved to treat psoriatic arthritis and plaque psoriasis in adults. How it works: Apremilast is an inhibitor ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...